GoodRx (GDRX) Citi's 2024 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Citi's 2024 Global Healthcare Conference summary
8 Jul, 2026Retail environment and industry dynamics
Store closures, especially Rite Aid's, caused a $5 million headwind in the second half, with concentrated closures in Ohio and Michigan having the most impact.
Pharmacies have gained leverage in negotiations with PBMs due to unsustainable reimbursement rates, leading to a broader range of expected top-line growth (single-digit %) for next year.
Most renegotiations are expected to culminate by year-end, with new rates manifesting in January and February.
The current volatility is seen as a one-time reset, not a recurring theme, as pharmacy leverage is situational.
CVS store closures had minimal impact due to geographic thinning, while Rite Aid's concentrated closures created more friction for users.
Direct contracting and business strategy
Direct contracting with pharmacies increases their revenue and margin, with about 30% of volume now through such agreements and eight of the top 10 pharmacies signed up.
The hybrid strategy allows flexibility, letting retailers dictate preferences between direct contracts and PBM partnerships.
Direct contracts provide more control and merchandising opportunities, benefiting both parties and allowing for tailored pricing.
No PBM has stopped working with the company; relationships have evolved, with some PBMs now distributing GoodRx through integrated programs.
Direct contracting volume may accelerate or decelerate depending on PBM-pharmacy negotiations, but the approach remains adaptable.
Integrated Savings Program (ISP) and growth levers
ISP has grown to 5% of marketplace revenue and is expected to maintain healthy double-digit growth, with new deals signed for ISP wrap targeting off-formulary medications.
The most impactful growth lever is adding more plans and plan sponsors, with direct outreach to employers being a new focus.
Marketing costs for ISP are similar to D2C, with PBMs handling most go-to-market efforts.
Pushback from employers is mainly due to caution with new products, but comfort grows after successful implementation.
MedImpact, SilverScript, SmithRx, and Navitus are signed up for ISP wrap, with ongoing discussions to add more PBMs.
Latest events from GoodRx
- 2024 revenue rose 6% to $792.3M with 32.8% margin; 2025 guidance targets further profitable growth.GDRX
Q4 20249 Jul 2026 - Pharma Direct surged 82% in Q1 2026, offsetting declines in other segments and raising guidance.GDRX
Q1 20268 Jul 2026 - Q1 2025 revenue up 3%, net income positive, and margins strong amid strategic growth and guidance.GDRX
Q1 20258 Jul 2026 - Direct contracting and scalable solutions drive growth and margin expansion amid industry shifts.GDRX
UBS Global Healthcare Conference 20248 Jul 2026 - Q3 2024 revenue up 8%, net income $4.0M, margin gains, and Pharma Solutions growth offset headwinds.GDRX
Q3 20248 Jul 2026 - All proposals passed, with directors elected and no shareholder questions submitted.GDRX
AGM 202616 Jun 2026 - Board recommends approval of all proposals at the virtual 2026 Annual Meeting.GDRX
Proxy filing29 Apr 2026 - Definitive additional proxy materials filed to inform shareholders of voting matters.GDRX
Proxy filing29 Apr 2026 - Sharpened strategy and robust growth in integrated savings and pharma solutions drive margin gains.GDRX
Morgan Stanley 22nd Annual Global Healthcare Conference5 Apr 2026